New member: Adjutec Pharma
Meet our new member Adjutec Pharma, a company with new technology against multi-drug resistant bacteria.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 276 entries.
Meet our new member Adjutec Pharma, a company with new technology against multi-drug resistant bacteria.
Helsenæringen er en dobbel mulighet for Norge.
Bemcentinib from the Norwegian biotech BerGenBio will be tested on COVID-19 patients.
Adapting cancer-fighting artificial intelligence technology to combat COVID-19.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.